

Wolfgang A Schmidt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11365872/publications.pdf>

Version: 2024-02-01

62
papers

6,571
citations

126907

33
h-index

133252

59
g-index

65
all docs

65
docs citations

65
times ranked

3862
citing authors

#	ARTICLE	IF	CITATIONS
1	Musculoskeletal ultrasound including definitions for ultrasonographic pathology. <i>Journal of Rheumatology</i> , 2005, 32, 2485-7.	2.0	848
2	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 636-643.	0.9	753
3	Color Duplex Ultrasonography in the Diagnosis of Temporal Arteritis. <i>New England Journal of Medicine</i> , 1997, 337, 1336-1342.	27.0	660
4	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 804-814.	0.9	504
5	Meta-Analysis: Test Performance of Ultrasonography for Giant-Cell Arteritis. <i>Annals of Internal Medicine</i> , 2005, 142, 359.	3.9	323
6	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. <i>Health Technology Assessment</i> , 2016, 20, 1-238.	2.8	313
7	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatism</i> , 2012, 64, 943-954.	6.7	273
8	The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1974-1979.	0.9	191
9	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. <i>RMD Open</i> , 2018, 4, e000598.	3.8	155
10	Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. <i>RMD Open</i> , 2017, 3, e000427.	3.8	149
11	Ultrasound in the diagnosis and management of giant cell arteritis. <i>Rheumatology</i> , 2018, 57, ii22-ii31.	1.9	139
12	OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On. <i>Journal of Rheumatology</i> , 2019, 46, 1388-1393.	2.0	133
13	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
14	International Consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise. <i>Rheumatology</i> , 2015, 54, 1797-1805.	1.9	122
15	Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. <i>Rheumatology</i> , 2017, 56, 1479-1483.	1.9	122
16	Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. <i>Current Opinion in Rheumatology</i> , 2005, 17, 9-15.	4.3	115
17	The OMERACT Ultrasound Task Force "Status and Perspectives. <i>Journal of Rheumatology</i> , 2011, 38, 2063-2067.	2.0	111
18	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. <i>Rheumatology</i> , 2018, 57, 227-235.	1.9	101

#	ARTICLE	IF	CITATIONS
19	The Diagnosis and Treatment of Giant Cell Arteritis. Deutsches Ärzteblatt International, 2013, 110, 376-85; quiz 386.	0.9	100
20	Role of ultrasound in the understanding and management of vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 39-47.	2.7	82
21	What is the best approach to diagnosing large-vessel vasculitis?. Best Practice and Research in Clinical Rheumatology, 2005, 19, 223-242.	3.3	78
22	The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12â€¦months of therapy. Annals of the Rheumatic Diseases, 2013, 72, 1163-1169.	0.9	77
23	Imaging in vasculitis. Best Practice and Research in Clinical Rheumatology, 2013, 27, 107-118.	3.3	74
24	Current state of musculoskeletal ultrasound training and implementation in Europe: results of a survey of experts and scientific societies. Rheumatology, 2010, 49, 2438-2443.	1.9	65
25	Imaging of vasculitis: State of the art. Best Practice and Research in Clinical Rheumatology, 2016, 30, 688-706.	3.3	64
26	Atherosclerosis as a potential pitfall in the diagnosis of giant cell arteritis. Rheumatology, 2018, 57, 318-321.	1.9	60
27	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56
28	The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology, 2018, 57, 112-119.	1.9	53
29	Technology Insight: the role of color and power Doppler ultrasonography in rheumatology. Nature Clinical Practice Rheumatology, 2007, 3, 35-42.	3.2	52
30	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. Journal of Rheumatology, 2018, 45, 1289-1295.	2.0	49
31	Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis?. Rheumatology, 2009, 48, 383-385.	1.9	46
32	Ultrasonography in inflammatory rheumatic disease: an overview. Nature Reviews Rheumatology, 2011, 7, 479-488.	8.0	38
33	Doppler sonography in rheumatology. Best Practice and Research in Clinical Rheumatology, 2004, 18, 827-846.	3.3	35
34	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1160-1166.	0.9	34
35	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. Annals of the Rheumatic Diseases, 2021, 80, 1475-1482.	0.9	34
36	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases, 2021, 80, 840-847.	0.9	31

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. <i>Trials</i> , 2021, 22, 543.	1.6	31
38	Head-to-head comparison of quantitative and semi-quantitative ultrasound scoring systems for rheumatoid arthritis: reliability, agreement and construct validity. <i>Rheumatology</i> , 2012, 51, 2034-2038.	1.9	30
39	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3717-3726.	1.9	26
40	Investigations in systemic vasculitis – The role of imaging. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 63-82.	3.3	25
41	Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis. <i>Rheumatology</i> , 2021, 60, 5052-5059.	1.9	25
42	Takayasu and Temporal Arteritis. , 2006, 21, 96-104.		23
43	Reliability Exercise for the Polymyalgia Rheumatica Classification Criteria Study: The Oranjewoud Ultrasound Substudy. <i>International Journal of Rheumatology</i> , 2009, 2009, 1-5.	1.6	23
44	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 2299-2307.	1.9	21
45	Current diagnosis and treatment of temporal arteritis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 145-151.	0.9	20
46	Clinical Applicability of Ultrasound in Systemic Large Vessel Vasculitides. <i>Arthritis and Rheumatology</i> , 2019, 71, 1780-1787.	5.6	19
47	The ultrasound halo sign of temporal arteries: is it always giant cell arteritis?. <i>Rheumatology</i> , 2019, 58, 1898-1899.	1.9	18
48	What the practising rheumatologist needs to know about the technical fundamentals of ultrasonography. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 981-999.	3.3	17
49	The new frontiers of ultrasound in the complex world of vasculitides and scleroderma. <i>Rheumatology</i> , 2012, 51, vii26-vii30.	1.9	17
50	Imaging in large-vessel vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101589.	3.3	15
51	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. <i>Rheumatology</i> , 2021, 60, 4361-4366.	1.9	15
52	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. <i>Lancet Rheumatology</i> , The, 2021, 3, e886-e895.	3.9	15
53	Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199850.	2.7	14
54	OMERACT definition and reliability assessment of chronic ultrasound lesions of the axillary artery in giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 951-956.	3.4	13

#	ARTICLE	IF	CITATIONS
55	Role of imaging in diagnosis of and differentiation between vasculitides. <i>Future Rheumatology</i> , 2006, 1, 627-634.	0.2	10
56	Temporal arteritis with ultrasound halo sign in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2069-2071.	1.9	8
57	Ultrasound in Rheumatology. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 711-715.	1.9	4
58	Whole-body MRI in RA: do we still need the rheumatologist?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 130-132.	8.0	2
59	Response to: "The role of temporal artery biopsy in patients with giant cell arteritis is debated"™ by Moiseev et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e32-e32.	0.9	1
60	Introduction: Musculoskeletal Ultrasound Indications and Fundamentals. , 2021, , 1-20.		1
61	FRIO274...ULTRASOUND CUT-OFF VALUE FOR INTIMA-MEDIA THICKNESS OF THE AXILLARY ARTERIES IN PATIENTS WITH CHRONIC LARGE-VESSEL GIANT CELL ARTERITIS. , 2019, , .		0
62	Polymyalgia Rheumatica and Giant Cell Arteritis in the Elderly. , 2011, , 225-229.		0